Table 2 Hepatitis B virus sero-reactivities, infection stages and genotypes in the study participants
| Â | Non-drug users | Non-injection drug users | Injection drug users | Â | ||
|---|---|---|---|---|---|---|
|  | HIV-1(−), n = 194 | HIV-1(−), n = 48 | HIV-1(+), n = 139 | HIV-1(−), n = 214 | HIV-1(+), n = 157 | P |
Sero-marker | Â | Â | Â | Â | Â | Â |
HBsAg | 5 (2.6) | 0 (0.0) | 5 (3.6) | 5 (2.3) | 15 (9.6) | 0.002 |
HBsAb | 16 (8.2) | 7 (14.6) | 12 (8.6) | 36 (16.8) | 13 (8.3) | 0.023 |
HBeAg | 0 (0.0) | 0 (0.0) | 1 (0.7) | 0 (0.0) | 0 (0.0) | - |
HBeAb | 13 (6.7) | 3 (6.3) | 13 (9.4) | 26 (12.1) | 21 (13.4) | 0.186 |
HBcAb-IgM | 9 (4.6) | 1 (2.1) | 9 (6.5) | 7 (3.3) | 16 (10.2) | 0.038 |
Infection stage | Â | Â | Â | Â | Â | Â |
1 | 3 (1.5) | 0 (0.0) | 0 (0.0) | 3 (1.4) | 9 (5.7) | - |
2 | 3 (1.5) | 0 (0.0) | 5 (3.6) | 2 (0.9) | 8 (5.1) | - |
3 | 11 (5.7) | 5 (10.4) | 9 (6.5) | 33 (15.4) | 10 (6.4) | 0.003 |
4 | 13 (6.7) | 3 (6.3) | 10 (7.2) | 24 (11.2) | 13 (8.3) | 0.479 |
5 | 164 (84.5) | 40 (83.3) | 115 (82.7) | 152 (71.0) | 117 (74.5) | 0.005 |
HBV genotypes | Â | Â | Â | Â | Â | Â |
A1 | 6 (3.1) | 0 (0.0) | 3 (2.2) | 4 (1.9) | 10 (6.4) | - |